NCT06514274 - Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication | Biotech Hunter

Enrollment

558

Participants

Timeline

Start Date

September 20, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

June 25, 2025

Conditions

Helicobacter Pylori InfectionChronic Gastritis

Interventions

DRUG

Berberine

Berberine 500 mg, twice daily for 14 days

DRUG

Vonoprazan

Vonoprazan 20 mg, twice daily for 14 days

DRUG

Amoxicillin

Amoxicillin 1000mg, twice daily for 14 days.

DRUG

Bismuth

Bismuth 220mg, twice daily for 14 days.

DRUG

Clarithromycin

Clarithromy 500mg, twice daily for 14 days.

DRUG

Esomeprazole

Esomeprazole 10mg, twice daily for 14 days.

Trial Locations (1)

Xijing Hosipital of Digestive Disease, Xi'an

All Listed Sponsors

lead

Xijing Hospital of Digestive Diseases

OTHER